Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1397

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Melanoma
Interventions: Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus Ipilimumab Cohort 3, Bevacizumab Plus Ipilimumab Cohort 4; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Myelodysplastic Syndromes (MDS)
Interventions: venetoclax, azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Tucson, Arizona • Aurora, Colorado • New Haven, Connecticut + 6 more

Conditions: Leukemia, Lymphoma
Interventions: rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant; Biological · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 69 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 25
States / cities: Duarte, California • Lewes, Delaware • Newark, Delaware + 18 more

Conditions: Atopic Dermatitis
Interventions: MSTT1041A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Colorado Springs, Colorado + 11 more

Conditions: Lung Cancer Patients, Caregivers
Interventions: There are no interventions in this study. All participants complete online surveys.; Other
Lead sponsor: LUNGevity Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ulcerative Colitis
Interventions: UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Greenville, North Carolina • Salt Lake City, Utah

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Venetoclax, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 21
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 18 more

Conditions: Proliferative Diabetic Retinopathy
Interventions: ranibizumab, Laser photocoagulation; Drug · Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
Interventions: Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Non-Hodgkin's Lymphoma, CNS Lymphoma
Interventions: Autologous stem cell transplant, High-dose chemotherapy; Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: COVID-19, Respiratory Failure, ARDS
Interventions: Tenecteplase, Placebo; Drug
Lead sponsor: Hooman Poor; Other
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions: Vigil, Atezolizumab; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma

Tenecteplase in Patients With COVID-19

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

About this Genentech, Inc. sponsor directory page